Research Article (Open access) |
---|
Int. J. Life. Sci. Scienti. Res.,
1(1):
8-11,
September 2015
In-vitro
Anti-Inflammatory Activity of Parkia Biglobosa Fruit
Bark Extract
Ukwuani AN*, Ahmad HB
Department of Biochemistry, Faculty of Science, Kebbi State University of Science and Technology, Aleiro, Kebbi State, P.M.B-1144
*Address for
Correspondence: Dr. Ukwuani AN, Department of Biochemistry,
Faculty of Science, Kebbi State University of Science
and Technology, Aleiro, Kebbi
State. P.M.B, 1144
ABSTRACT-
The
in-vitro anti-inflammatory activity
of various solvent fractions of Parkia biglobosa fruit bark was investigated using human red blood cell
membrane stabilization, heat-induced hemolysis and
protein denaturation methods. All the extracts of P. biglobosa
fruit bark showed a concentration dependent increase in anti-inflammatory
activity. The anti-inflammatory activity of the crude extract (60.8%, 58.3%,
78.2%) and last remaining aqueous extract (61.1%, 54.1%, 77.2%) have the
maximum membrane stabilization, protection against hemolysis
and albumin denaturation respectively which was
comparable to Diclofenac sodium (61.4%, 60.6%, 100%)
at 400µg/ml concentration. This study suggests that P. biglobosa fruit bark posses enough
potential to reduce inflammation by In-vitro,
hence directs the importance of further research and development of novel
anti-inflammatory agents.
KEY WORDS: In-vitro, Anti-inflammatory, fruit bark, HRBC membrane
stabilization, hemolysis, protection
INTRODUCTION-
Inflammation is the reaction of
living tissue to injury, infection or irritation. It involves complex array of
enzyme activation, mediator release, fluid extravasations, cell migration,
tissue breakdown and repair [1] which is aimed at host defence and usually activated in most disease condition. Drugs which are in use presently for
the management of pain and inflammatory conditions are either narcotics e.g. opioids or non-narcotics e.g. salicylates
and corticosteroids e.g. hydrocortisone. Due to risk of adverse
effects encountered with the use of synthetic anti-inflammatory drugs, natural
products derived from plants may offer an alternative source of
anti-inflammatory agent. The use of traditional medicine and medicinal plants
in most developing countries, as a normotive basis
for the maintenance of good health, has been widely observed [2].
Parkia
biglobosa is widely acclaimed by
the Hausa communities of northern Nigeria for the treatment of diseases such as
malaria, diabetes mellitus and pains. The stem barks is boiled in water and
taken as a decoction for the treatment of malaria, inflammatory diseases and
infections to diarrhea [3]. The bark soaked in ethanol is also used in some
communities for anti-diarrhoeal properties and as
effective anti- snake venoms that protects against neurotoxic,
haemotoxic and cytotoxic effects of poisonous snakes
[4]. Also, the leaves, fruits and seeds of P. biglobosa
have also been used to manage various diseases [5].
MATERIALS AND METHODS
Plant
material collection and preparation- The fruit back of P.
biglobosa were collected in April, 2014 from BirninYauri Town, Ngaski Local
Government Area, Kebbi State, Nigeria. The plant was
identified by their local names and later authenticated by the herbarium at
Department of Biological Sciences, Kebbi State
University of Science and Technology, Aliero with a
voucher specimen (No 281). Fresh fruit bark were air-dried and grinded into
coarse powder using mortar and pestle.
Extraction of the plant material-
Crude extraction was carried out according to the method of Edeoga
et al [6] with slight modifications.
One kilogram (1.0 kg) of the fruit bark powder was extracted with hydromethanolic solvent (methanol (70): water (30)) for 72
hours. This was then filtered and evaporated to dryness in an oven at 45oc to
give hydromethanolic crude extract (346g).
Phytochemical
analysis- Preliminary phytochemical
studies were conducted as per standard procedures described by Trease and Evan [7] and Harbone
[8]
Solvent
Partitioning of the Methanolic Extract- Hydromethanolic
extract (100g) was redissolved in distilled water
(200 mL) in a separating funnel and partitioned with n-hexane
(4 × 200 mL). The resulting n-hexane phase was
concentrated to dryness and known as hexane fraction which was stored in a
freezer in an air-tight container. The resulting aqueous phase was further
partitioned with chloroform, ethyl acetate and butanol
respectively. The last remaining aqueous fraction was then evaporated to
dryness and kept for further use in the freezer in an air-tight container [6].
In-vitro anti inflammatory studies
Preparation of
Red Blood cells (RBCs) suspension- Fresh whole human blood (5mL) was
collected and transferred to the centrifuged tubes containing Heparin or EDTA
or Sodium citrate to prevent clotting. The tubes were centrifuged at 3000 rpm
for 10 min and were washed three times with equal volume of normal saline. The
volume of the blood was measured and reconstituted as 10% v/v suspension with
normal saline [9].
The
human red blood cell (HRBC) membrane stabilization method- The
reaction mixture consist of 1.0ml of test sample of different concentration
(50-400µg/ml) in normal saline and 0.5 ml of 10% HRBC suspension, 1 ml of 0.2 M
phosphate buffer, 1 ml hypo saline were incubated at 37C for 30 min and
centrifuged at 3000 rpm for 20 min and the hemoglobin content of the
supernatant solution was estimated spectrophotometrically
at 560 nm. Diclofenac sodium was used as standard and
a control was prepared without extracts [10]. The percentage of hemolysis and membrane stabilization or protection was
calculated by using the following formula;
% of Hemolysis =
(Optical density of test sample / Optical density of control) X 100
% Protection = 100 – [(Optical density of
test sample / Optical density of control) X 100
Heat induced human red blood cell (HRBC) membrane stabilization method- The reaction mixture in heat induced hemolysis consists of 1.0 ml of test sample of different concentrations (50μg – 400μg/ml) in normal saline and 1.0 ml of 10% RBC suspension. Diclofenac sodium was taken as a standard drug. Control was prepared by distilled water instead of normal saline to produce 100 % hemolysis without plant extracts. All the tubes containing reaction mixture were incubated in a water bath at 560 C for 30 min. After incubation, the tubes were cooled under running tap water. The reaction mixture was centrifuged at 2500 rpm for 5 min and the absorbance of the supernatants was taken at 560 nm [11]. The experiment was performed in triplicates. The percentage of HRBC hemolysis and membrane stabilization or protection was calculated by using the following Formula:
% of Hemolysis =
(Optical density of test sample / Optical density of control) X 100
% Protection = 100 – [(Optical density of
test sample / Optical density of control) X 100]
Albumin denaturation method- Protein denaturation was performed as described by Elias et al. [12] with slight modifications. The reaction mixture consists of 1.0 ml of distilled water containing varied concentrations of plant extracts or standard (50μg – 400 μg), 0.2 ml of .05 % BSA and 1.8 ml of 0.2 M phosphate buffered saline (pH 6.4). The mixtures were incubated at 37ºC for 15 minutes and then heated at 70ºC for 5 minutes. After cooling, the absorbance was measured spectrophotometrically at 660nm against a blank. Diclofenac sodium was used as standard drug and the percentage inhibition of protein denaturation was calculated by using the following formula;
% Inhibition=100 ×[Vt/Vc-1]
Where, Vt = absorbance of test sample; Vc
= absorbance of control
RESULTS
AND DISCUSSION
Percentage
Yield and Phytochemistry- The percentage yield of 1000g of P. biglobosa fruit bark using hydromethanolic
extraction was 34.6% while fractionation of 100g of hydromethanolic
extract of P. biglobosa fruit bark obtained
percentage yield as presented in Table 1, whereas Phytochemical
screening which revealed the present of secondary metabolites as shown below in
Table 2.
Table 1: Percentage yield of P.
biglobosa fruit bark (100g)
Fraction |
Percentage yield (%) |
Hexane |
28.6 |
Chloroform |
23.5 |
Ethyl acetate |
21.2 |
Butanol |
4.4 |
Last remaining aqueous fraction |
14.8 |
Table 2:
Preliminary Phytochemical screening of P.
biglobosa fruit bark
Phytochemicals |
Result |
Alkaloids |
+ |
Tannins |
++ |
Saponins |
ND |
Flavonoids |
+++ |
Steroids |
++ |
Cardiac glycosides |
+ |
Reducing sugar |
++ |
(+)trace
amount, (++) moderately present, (+++) highly present, (ND)Not Detected
Membrane
stabilization activity of P. biglobosa fruit bark- Lysosomal
enzymes released during inflammation produce a variety of disorders. The extra
cellular activity of these enzymes is said to be related to acute or chronic
inflammation. The non steroidal drugs act either by inhibiting these lysosomal enzymes or by stabilizing the lysosomal
membrane [13]. The in-vitro
anti-inflammatory activity of P. biglobosa fruit bark fractions were assessed by HRBC
membrane stabilization method (Figure 1). Crude extract and fractions of P. biglobosa
fruit bark exhibited varying degree of anti-inflammatory activity which was
comparable to the standard drug Diclofenac sodium.
The result showed a concentration dependent increase in percentage protection
of the membrane in all the tested fractions.
Fig. 1: Membrane Stabilization
Effect of Parkia biglobosa
fruit bark
Since the human red blood cell membrane is analogous to the lysosomal
membrane [14], its stabilization indicates the stabilization of lysosomal membranes. Stabilization of the membranes of these
cells inhibits lysis and subsequent release of the cytoplasmic contents which in turn limits the tissue damage
and exacerbation of the inflammatory response [15]. In this study, P. biglobosa
fruit bark was able to confer a significant protection of HRBC membrane when
compared to Diclofenac sodium.
Inhibition of Heat-induced hemolysis- Exposure
of red blood cells to hypotonic medium, heat, injurious substances such as
methyl salicylate or phenylhydrazine
results in the lysis of membranes accompanied by haemolysis and oxidation of haemoglobin
[16]. The effect of P. biglobosa fruit bark on hypotonicity-induced
hemolysis is presented in Figure 2. At the highest
dose (400µg/ml), hydromethanolic crude extract and
last remaining aqueous fraction was capable of protecting the membrane by 60.8%
and 61.1% which was not significantly different from the standard drug Diclofenac sodium. The prevention of heat-induced HRBC
membrane lysis is taken as measure of
anti-inflammatory activity of P. biglobosa fruit bark.
Fig.
2: Effect of Parkia biglobosa
Fruit Bark on Heat-Induced Hemolysis
Albumin Denaturation-
Protein denaturation is the process in which protein
lose their secondary and tertiary
structure by application of external stress or compounds such as strong
acid or base, organic solvent or heat [17]. Denaturation
of protein is a well documented cause of inflammation. In the present study, P.
biglobosa
fruit bark was effective in inhibiting albumin denaturation
(Figure 3). Maximum inhibition of 78.2% and 77.2% was observed in hydromethanolic extract and last remain aqueous fraction
respectively at a concentration of 400µg/ml. On the other hand, Diclofenac sodium, the standard anti-inflammatory drug
showed a maximum inhibition of 100%. The increased percentage of inhibition of
albumin denaturation expresses the anti-inflammatory
efficacy of P. biglobosa fruit bark.
Fig. 3: Effect of Parkia biglobosa
Fruit Bark on Albumin Denaturation
CONCLUSIONS-
The
present study indicates that
the different solvent extract of P. biglobosa fruit bark possess anti-inflammatory
property. This activity may be due to presence of phenolic compounds such as
flavonoids and tannins. This in-vitro
study is a preliminary evaluation of anti-inflammatory activity of Parkia biglobosa fruit bark and validates the folkloric use
of this plant in the treatment of inflammatory conditions. Further research
work to evaluate in vivo activity on animals, isolation and characterization of
its bioative components is recommended.
REFERENCES
1. Vane
JR, Bottling RM. New insights into the model of action of anti-inflammatory
drugs. Inflamm. Res. 1991; 44(1): 1 – 10.
2. UNESCO
(1996). Culture and Health, Orientation Texts – World Decade for
Cultural Development 1988 – 1997, Document CLT/DEC/PRO – 1996, Paris, France,
Pp. 129.
3. Asase
A, Alfred A, Yeboah O, Odamtten
GT, Simmonds SJ. Ethnobotanical study of some
Ghanaian antimalarial plant. J. Ethnopharmacol. 2005; 99: 273-279.
4. Agunu
A, Yusuf S, Andrew O, Gabriel U, Abdulkadir M. et al. Evaluation of five medicinal
plants used in diarrhea treatment in Nigeria. J. Ethnopharmacol 2001; 101: 27-30.
5. Builders
MI, Aguiyi JC. Toxicity studies of the extracts of Parkia biglobosa
stem bark in rats. Brit. J. Pharmaceut. Res. 2012; 2(1): 1-16.
6. Edeoga
HO, Okwu DE, Mbaebe BO.
Phytochemical constituent of some Nigerian medicinal plants. Afr. J. Biotechnol. 2005,
685–688.
7. Trease GE, Evans WC. Pharmacognosy. 13th (ed). ELBS/Bailliere Tindall, London. 1989; 345-6, 535-6, 772-3.
8. Harborne JB. Phytochemical Methods. Chapman and Hall Ltd., London, UK., 1973; pp: 49-188.
9. Sadique J, Al –Raqobah WA, Bugharith ME and El-Gindy AR. (1989).The bioactivity of certain medicinal
plants on the stabilization of RBC membrane system. Fitoterapia. 1989; 60 (6): 525-532.
10. Gandhisan
R, Thamaraichelvan A, Baburaj
A. Anti-inflammatory action of Lanneacoromandelica
HRBC membrane stabilization. Fitotherapia.
1991; 62:82- 83.
11. Shinde U A, Phadke AS, Nair AM, Mugantiwar
AA, Dikshit VJ and Saraf
VO. Membrane stabilizing activity - A possible mechanism of action for the
anti-inflammatory activity of Cedrusdeodara wood oil. Fitoterapia. 1999; 70 (3): 251-257.
12. Elais G, Rao MN. Inhibition of
albumin denaturation and anti-inflammatory activity
of dehydrozingerone and its analogs. Indian J. Exp. Biol.1988; 26(10): 540 –
543.
13. Rajendran V, Lakshmi KS. In vitro
and in vivo anti inflammatory activity of leaves of Symplocosco chinchinensis (Lour) Moore. Bangladesh J Pharmacol.2008; 3; 121-124.
14. Chou
CT. The anti-inflammatory effect of Tripterygium
wilfordii Hook on adjuvant induced paw edema in
rats and inflammatory mediators release. Phytother Res. 1997; (11):152-154.
15. Charles OO, Peter AA, Nkemjika
JO, Theophine CN, Anthonia
CO, Chukwuemeka SN. “Acanthus montanus:
An experimental evaluation of the antimicrobial, anti-inflammatory and
immunological properties of a traditional remedy for furuncles”. BMC Complementary and Alternative Medicine.
2008; (8): 27.
16. Ferrali M, Signorni C, Ciccoli
L, Comporti M. (1992). Iron release and
membrane damage in erythrocytes exposed to oxidizing agents phenylhydrazine,
divicine and isouramil. Biochemical
Journal. 1992; 285(1):295-301.
17. Megha
GC, Bhoomi BJ, Kinnari NM. In Vitro Antidiabetic
and Anti-inflammatory activity of Stem Bark of Bauhinia Purpurea.
Bull. Pharmaceut.
Med. Sci. 2013; 1(2): 139 – 150.